New insights regarding chronic antibody-mediated rejection and its progression to transplant glomerulopathy

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 6, 2014, Pages 611-618

  Schinstock, Carrie A ^a   Stegall, Mark ^a   Cosio, Fernando ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibody mediated rejection; Donor specific antibody; Positive crossmatch transplantation; Transplant glomerulopathy

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; ALLOANTIBODY;

ANTIBODY MEDIATED REJECTION; CELL ACTIVATION; CHRONIC ANTIBODY MEDIATED REJECTION; COMPLEMENT ACTIVATION; DISEASE COURSE; ENDOTHELIUM CELL; GLOMERULOPATHY; GRAFT FAILURE; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY GRAFT; LYMPHOCYTIC INFILTRATION; MONOCYTE; NATURAL KILLER CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TRANSPLANT GLOMERULOPATHY; ADVERSE EFFECTS; ANIMAL; CHRONIC DISEASE; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; IMMUNOLOGY; KIDNEY; KIDNEY TRANSPLANTATION; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; CHRONIC DISEASE; DISEASE PROGRESSION; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMANS; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84927646236     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000070     Document Type: Review

References (54)

1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11:450-462.
2. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9:527-535.
3. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90:68-74.
4. Sellares J, de Freitas DG, MengelM, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12:388-399.
5. Wavamunno MD, O'Connell PJ, Vitalone M, et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant 2007; 7:2757-2768.
6. Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant 2008; 8:492-496.
7. John R, Konvalinka A, Tobar A, et al. Determinants of long-term graft outcome in transplant glomerulopathy. Transplantation 2010; 90:757-764.
8. Halloran PF, Wadgymar A, Ritchie S, et al. The significance of the anticlass I antibody response. I. Clinical and pathologic features of anticlass I-mediated rejection. Transplantation 1990; 49:85-91.
9. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010; 15:42-48.
10. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9:2312-2323.
11. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7:2124-2132.
12. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: risk and prognosis related to antihuman leukocyte antigen class II antibody levels. Transplantation 2008; 86:681-685.
13. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7:1743-1752.
14. Roufosse CA, Shore I, Moss J, et al. Peritubular capillary basement membrane multilayering on electron microscopy: a useful marker of early chronic antibody-mediated damage. Transplantation 2012; 94:269-274.
15. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5:2464-2472.
16. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14:272-283.
17. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67:2415-2421.
18. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12:574-582.
19. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005; 80:1194-1197.
20. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7:408-415.
21. Akiyoshi T, Hirohashi T, Alessandrini A, et al. Role of complement and NK cells in antibody mediated rejection. Hum Immunol 2012; 73:1226-1232.
22. Valenzuela NM, Reed EF. The link between major histocompatibility complex antibodies and cell proliferation. Transplant Rev (Orlando) 2011; 25:154-166.
23. Jindra PT, Hsueh A, Hong L, et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol 2008; 180:2214-2224.
24. von Willebrand E, Lautenschlager I, Inkinen K, et al. Distribution of the major histocompatibility complex antigens in human and rat kidney. Kidney Int 1985; 27:616-621.
25. Cornell LD, Gloor JM, Raghavaiah S, et al. Chronic antibody mediated histologic changes in positive-crossmatch kidney transplants (plus XMKTx) receiving early C5 blockade. Am J Transplant 2012; 12:450-1450.
26. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10:1812-1822.
27. Tellides G, Tereb DA, Kirkiles-Smith NC, et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000; 403:207-211.
28. Cai J, Terasaki PI, Mao Q, et al. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006; 6:2947-2954.
29. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6:1841-1847.
30. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10:2208-2214.
31. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13:779-787.
32. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43:1333-1338.
33. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753-760.
34. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405-2413.
35. Toyoda M, Ge S, Suviolahti E, et al. IFN-g production by NK cells from HLAsensitized patients after in vitro exposure to allo-antigens. Transpl Immunol 2012; 26:107-112.
36. Bergese SD, Huang EH, Pelletier RP, et al. Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-alpha or IL-4 and is not required for allograft rejection. Am J Pathol 1995; 147:166-175.
37. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13:76-85.
38. Husain S, Sis B. Advances in the understanding of transplant glomerulopathy. Am J Kidney Dis 2013; 62:352-363.
39. Loupy A, Hill GS, Nochy D, Legendre C. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2010; 10:952; author reply 953.
40. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibodymediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12:1168-1179.
41. Cosio FG, Lager DJ, Lorenz EC, et al. Significance and implications of capillaritis during acute rejection of kidney allografts. Transplantation 2010; 89:1088-1094.
42. Lerut E, Naesens M, Kuypers DR, et al. Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation 2007; 83:1416-1422.
43. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9:2520-2531.
44. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donorspecific antibodies (DSA). Am J Transplant 2011; 11:56-65.
45. Kieran N, Wang X, Perkins J, et al. Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. J Am Soc Nephrol 2009; 20:2260-2268.
46. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10:582-589.
47. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95:410-417.
48. Baid-Agrawal S, Lachmann N, Budde K. Complement-binding anti-HLA antibodies and kidney transplantation. N Engl J Med 2014; 370:84.
49. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibodymediated rejection in heart transplant recipients. J Heart Lung Transplant 2013; 32:98-105.
50. Walsh RC, Alloway RR, Girnita AL, Woodle ES. Proteasome inhibitorbased therapy for antibody-mediated rejection. Kidney Int 2012; 81: 1067-1074.
51. Morrow WR, Frazier EA, Mahle WT, et al. Rapid reduction in donor-specific antihuman leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 2012; 93:319-324.
52. Theruvath TP, Saidman SL, Mauiyyedi S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72:77-83.
53. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157-1167.
54. El Ters M, Grande JP, Keddis MT, et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant 2013; 13:2334-2341.